Shinde. G.S., Prasad Kumbhar, Jadhav. R.S., Vikhe. D. N
Shinde. G.S.1*, Prasad Kumbhar1, Jadhav. R.S.2, Vikhe. D. N2
1Department of Pharmaceutical Chemistry, Pravara Rural College of Pharmacy, Pravaranagar. Tal - Rahata, Dist.- Ahmednagar.
2Department of Pharmacognosy, Pravara Rural College of Pharmacy, Pravaranagar. Tal - Rahata, Dist.- Ahmednagar.
Volume - 12,
Issue - 4,
Year - 2022
Monoclonal antibodies are antibodies that are identical because they were produced by one type of immune cell, all Human monoclonal antibody immunotherapy in clinical medicine has been an exciting prospect for some time, and increasing numbers of such antibodies have gradually become available. Targets and basic characterization of novel classes of bioactive agents, to the development of ‘designer’ or ‘smart’ materials which provide required excipient or carrier properties to achieve modulated and targeted drug delivery. Drug particle engineering, or crystal engineering, provides an additional dimension to drug delivery and targeting. Traditional methods of particle formation, crystallization. Antibodies can be heterogeneous with respect to size, charge, antigen specificity, and affinity. These factors may be significant when antibodies are used as a drug delivery system. Drug targeting and delivery using antibodies has been most useful in the field of chemotherapy because this is an area of research in which there is the greatest need for target-site specificity. Antibodies have been found to have many applications in the management of human carcinomas, including colorectal, gastric, ovarian, endometrial, breast, lung.
Cite this article:
Shinde. G.S., Prasad Kumbhar, Jadhav. R.S., Vikhe. D. N. Monoclonal Antibodies as a Site Specific Particulate Drug Delivery System: A Review. Asian Journal of Pharmaceutical Analysis. 2022; 12(4):286-2. doi: 10.52711/2231-5675.2022.00047
Shinde. G.S., Prasad Kumbhar, Jadhav. R.S., Vikhe. D. N. Monoclonal Antibodies as a Site Specific Particulate Drug Delivery System: A Review. Asian Journal of Pharmaceutical Analysis. 2022; 12(4):286-2. doi: 10.52711/2231-5675.2022.00047 Available on: https://ajpaonline.com/AbstractView.aspx?PID=2022-12-4-12
1. Larson, S.M., Brown, J.P., Wright, P.W., Carrasquillo, J.A., Hellstrom, I., andhellstrom, K.E., Imaging of melanoma with I-labeled monoclonal antibodies, J. Nuclear Med. 24, 123–129, 1983.
2. Zurawski, V.R., Haber, E., and Black, P.H., Production of antibody to tetanus Toxoid by continuous human lymphoblastoid cell lines, Science, 199, 1439,1978.
3. Trout, A., Increased selectivity of drugs by linking to carriers, Eur. J. Cancer,14, 105, 1978.
4. Steinitz, M., Klein, G., Koskimies, S., and Makela, O., EB virus-induced B-lymphocyte Cell lines producing specific antibody, Nature, 269, 420, 1977.
5. Birch, J.R., Cells sell, Chemtech, 17(6), 378–381, 1987.
6. Rowland, G.F., Davies, D.A.L., O’Neill, G.I., Newman, C.E., and Ford, C.H.J., Specific cancer therapy by drugs synergising with or attached to tumor-specificantibodies: experimental background and clinical results. In Immunotherapyof Malignant Diseases, Rainer, H., Ed., Schattauer-Verlag, Stuttgart, 1977,316–322.
7. Hurwitz, E., Maron, R., Wilcheck, M., Arnon, R., and Sela, M., The covalentbinding of daunomycin and adriamycin to antibodies with retention of bothdrug and antibody activities, Cancer Research, 35, 1175–1181, 1975.
8. Rowland, G.F., O’Neill, G.I., and Davies, D.A.L., Suppression of tumor growthin mice by a drug-antibody conjugate using a novel approach to linkage, Nature, 255, 487–488, 1975.
9. Kadin, S.B. and Otterness, I.G., Antibodies as drug carriers and toxicity-reversalagents, Ann. Rep. Med. Chem., 15, 233–244, 1980.
10. Upselacis, J. And Hinman, L., Chemical modification of antibodies for cancerchemotherapy, Ann. Rep. Med. Chem., 23, 151–160, 1988.
11. Kohler, G. And Milstein, C., Continuous cultures of fused cells secreting antibodyof predefined specificity, Nature, 256, 495, 1975.
12. Gilliland, D.G., Steplewski, Z., Collier, R.J., Mitchell, K.F., Chang, T.H., andkoprowski, H., Antibody-directed cytotoxic agents: Use of monoclonal antibodyto direct the action of toxin A chains to colorectal carcinoma cells, Proc.Natl. Acad. Sci. USA, 77, 4539, 1980.
13. Sickle-Santanello, B.J. et al., Radioimmunoguided surgery using monoclonalantibody B72.3 in colorectal tumors, Dis. Col. Rectum, 30, 761–764, 1987.
14. Greiner, J.W. et al., Recombinant interferon enhances monoclonal antibody-Targeting of carcinoma lesions in vivo, Science, 235(4791), 895–898, 1987.
15. Rowland, G.F., The use of antibodies and polymer conjugates in drug targeting and synergy. In Target Drugs, Goldberg, E., Ed., John Wiley & Sons, New York, 1983, 57–72.
16. Jarvis, A.P. Jr., Producing monoclonal antibodies for clinical investigations. In The Latest Developments in Drug Delivery Systems, Conference Proceedings, Pharm. Tech., 11, 48–53, 1987.
17. Holyoke, E.D. and Petrelli, N.J., Tumor markers and monoclonal antibodies: An update, Medical Times, 57–63, 1987.
18. Olsson, L. And Kaplan, H., Human-human hybridomas producing monoclonal Antibodies of predefined antigenic specificity, Proc. Nat. Acad. Sci. USA, 77, 5429, 1980.
19. Lebherz III, W.B., Batch production of monoclonal antibody by large-scalesuspension culture, Biopharm, Feb. 1988, 22.
20. Familletti, P.G., Gel-immobilized cell culture for monoclonal antibody production, Biopharm, Nov. 1987, 48.
21. Hurwitz, E., Maron, R., Wilcheck, M., Arnon, R., and Sela, M., The covalentbinding of daunomycin and adriamycin to antibodies with retention of bothdrug and antibody activities, Cancer Research, 35, 1175–1181, 1975. Affinity
22. Steward MW and Steensgaard J. Antibody Affinity: thermodynamicaspects and Biological Significance. Boca Raton: CRC Press, 1983.
23. Alexander J and Dayal Y. Appl Immunohistochem 1997;5(4):252-3.24.
24. Herlyn, M., Steplewski, Z., Herlyn, D., and Koprowski, H., Colorectal carcinoma-specific antigen detection by means of monoclonal antibodies, Proc.Nat. Acad. Sci. USA, 76, 1438, 1979.
25. Hellstrom, I., Hellstrom, K.E., Brown, J.P., and Woodbury, R.G., Antigens ofhuman tumors, particularly melanomas, as studied with the monoclonal antibodytechnique. In Monoclonal Antibodies and T-Cell Hybridoma Perspectives and Technological Advances, Hammering, G.J., Hammerling, Y. And Kearney, J. F., Eds., Elsevier, Amsterdam, 1981, 191.
26. Kennett, R.H. and Gilbert, F., Hybrid myelomas producing antibodies against A human neuroblastoma antigen present on fetal brain, Science, 203, 1120, 1979.
27. Schlom, J., Monoclonal antibodies in cancer therapy: the present and thefuture, Biopharm, Sept. 1988, 44–48.
28. Schlom, J. And Weeks, M.O., Potential clinical utility of monoclonal antibodies. In The Management of Human Carcinomas in Important Advances in Oncology, devita, V., Hellman, S., and Rosenberg, S., Eds., J.B. Lippincott, Philadelphia,1984, 170–192.
29. Order, S.E., Analysis, results and future prospective of the therapeutic use ofradiolabelled antibody in cancer therapy. In Monoclonal Antibodies for cancerdetection and Therapy, Baldwin R.W. and Byers, V.S., Eds., Academic Press, London, 1985, 304–306.
30. O’Neill, G.J., The use of antibodies as drug carriers. In Drug Carriers in Biology and Medicine, Gregoriadis, G., Ed., Academic Press, Inc., London, 1979, 23–41.
31. Rowland, G.F., Use of antibodies to target drugs to tumor cells, Clinics inallergy and Immunology, 8, 2, 235–257, 1983.
32. Hockey, M.S., Stokes, H.J., Thompson, H., Woodhouse, C.S., macdonald, F., Fielding, J.W.I., and Ford, C.H.I., Carcinoembryonic antigen (CEA) expressionand heterogeneity in primary and autologous metastatic gastric tumors demonstratedby a monoclonal antibody, Br. J. Cancer, 49, 192–233, 1984.
33. Philpott, G.W., Grass, E.H., and Parker, C.W., Affinity cytotoxicity with analcohol dehydrogenase-antibody conjugate and allyl alcohol, Cancer Res., 39,2084, 1979.
34. Melchers, F., Potter, M., and Warnen, N.L., Eds., Lymphocyte hybridomas, Curr. Top. Microbiol. Immunol. 81, 246, 1978.
35. D‘Eustachio, P. And Ruddle, F.H., Current Topics in Developmental Biology, Vol.14, Frieldlander, M., Ed., Academic Press, New York, 1980, 59.
36. Bernstein, I.D., Tam, M.R., and Nowinski, R.C., Mouse leukemia therapy withmonoclonal antibodies against a thymus differentiation antigen, Science, 207,68.
37. Waldmann, Thomas A. (2003). "Immunotherapy: past, present and future". Nature Medicine (3):269–277. Doi:10.1038/nm0303-269. PMID 12612576. Http://www.nature.com/cgi-taf/dynapage.taf?File=/nm/journal/v9/n3/full/nm0303-269.html&filetype=pdf.
38. Thomas Boenich M.S., ICH staring method, fifty edition-7-8.
39. Rang, H. P. (2003). Pharmacology. Edinburgh: Churchill Livingstone. Pp. 241, for the examples infliximab, basiliximab, abciximab, daclizumab, palivusamab, gemtuzumab, alemtuzumab and rituximab, and mechanism and mode. ISBN 0-443-07145-4.
40. Sridhar Rao P.N (www.microrao.com)
41. Modified from Carter P (November 2001). "Improving the efficacy of antibody-based cancer therapies". Nat. Rev. Cancer 1 (2): 118–29. Doi:10.1038/35101072. PMID 11905803.
42. Engvall E and Perlmann P (1971). Enzyme linked immunosorbent assay (ELISA) quantitative assay of immunoglobulin G. Immunochemistry, v8 p871-875.
43. J. P. Adloff and R. Guillaumont, Fundamentals of Radiochemistry by CRC Press, Boca Raton (1993).
44. Betageri, G.V., Jenkins, S.A., and Ravis, W.R., Drug delivery using antibody-liposome Conjugates, Drug Dev. Ind. Pharm., 19/16, 2109–2116, 1993.